Charles River Laboratories Intl. Inc (NYSE:CRL) Shares Sold by Westfield Capital Management Co. LP

Westfield Capital Management Co. LP cut its position in shares of Charles River Laboratories Intl. Inc (NYSE:CRL) by 1.5% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 231,142 shares of the medical research company’s stock after selling 3,535 shares during the quarter. Westfield Capital Management Co. LP’s holdings in Charles River Laboratories Intl. were worth $33,573,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in CRL. BlackRock Inc. grew its stake in shares of Charles River Laboratories Intl. by 1.3% in the first quarter. BlackRock Inc. now owns 4,587,801 shares of the medical research company’s stock valued at $666,379,000 after buying an additional 57,789 shares in the last quarter. First Trust Advisors LP grew its stake in shares of Charles River Laboratories Intl. by 28.0% in the fourth quarter. First Trust Advisors LP now owns 1,099,399 shares of the medical research company’s stock valued at $124,430,000 after buying an additional 240,437 shares in the last quarter. Brown Advisory Inc. grew its stake in shares of Charles River Laboratories Intl. by 1.0% in the fourth quarter. Brown Advisory Inc. now owns 799,228 shares of the medical research company’s stock valued at $90,457,000 after buying an additional 7,663 shares in the last quarter. Norges Bank acquired a new stake in shares of Charles River Laboratories Intl. in the fourth quarter valued at about $61,460,000. Finally, Dimensional Fund Advisors LP grew its stake in shares of Charles River Laboratories Intl. by 0.6% in the first quarter. Dimensional Fund Advisors LP now owns 508,313 shares of the medical research company’s stock valued at $73,830,000 after buying an additional 2,978 shares in the last quarter. Institutional investors own 94.72% of the company’s stock.

CRL traded down $2.56 on Friday, reaching $129.41. The company’s stock had a trading volume of 285,623 shares, compared to its average volume of 262,240. The company has a market capitalization of $6.31 billion, a P/E ratio of 21.46, a P/E/G ratio of 1.70 and a beta of 1.05. Charles River Laboratories Intl. Inc has a 1 year low of $103.00 and a 1 year high of $149.07. The company has a debt-to-equity ratio of 1.10, a quick ratio of 1.39 and a current ratio of 1.63.

Charles River Laboratories Intl. (NYSE:CRL) last issued its quarterly earnings results on Tuesday, May 7th. The medical research company reported $1.40 EPS for the quarter, beating analysts’ consensus estimates of $1.38 by $0.02. The firm had revenue of $604.57 million during the quarter, compared to the consensus estimate of $587.65 million. Charles River Laboratories Intl. had a return on equity of 23.03% and a net margin of 9.63%. Charles River Laboratories Intl.’s revenue for the quarter was up 22.4% on a year-over-year basis. During the same quarter in the prior year, the business posted $1.29 earnings per share. As a group, equities research analysts forecast that Charles River Laboratories Intl. Inc will post 6.48 earnings per share for the current fiscal year.

In other Charles River Laboratories Intl. news, insider William D. Barbo sold 4,905 shares of the stock in a transaction that occurred on Wednesday, May 29th. The stock was sold at an average price of $125.16, for a total transaction of $613,909.80. Following the transaction, the insider now owns 25,859 shares of the company’s stock, valued at approximately $3,236,512.44. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, Director George Massaro sold 3,140 shares of the stock in a transaction that occurred on Friday, May 10th. The stock was sold at an average price of $134.64, for a total value of $422,769.60. Following the transaction, the director now directly owns 15,344 shares in the company, valued at approximately $2,065,916.16. The disclosure for this sale can be found here. Insiders sold 9,047 shares of company stock valued at $1,168,322 in the last three months. 1.80% of the stock is currently owned by company insiders.

A number of research firms have recently issued reports on CRL. Zacks Investment Research upgraded Charles River Laboratories Intl. from a “sell” rating to a “hold” rating in a research note on Thursday, May 9th. Wolfe Research began coverage on Charles River Laboratories Intl. in a research note on Tuesday, April 2nd. They issued a “market perform” rating for the company. Barclays increased their target price on Charles River Laboratories Intl. from $135.00 to $145.00 and gave the company an “equal weight” rating in a research note on Monday, March 18th. Svb Leerink began coverage on Charles River Laboratories Intl. in a research note on Monday, June 10th. They issued an “outperform” rating and a $155.00 target price for the company. Finally, KeyCorp increased their target price on Charles River Laboratories Intl. from $140.00 to $151.00 and gave the company an “overweight” rating in a research note on Monday, March 11th. Seven equities research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus target price of $146.27.

TRADEMARK VIOLATION WARNING: “Charles River Laboratories Intl. Inc (NYSE:CRL) Shares Sold by Westfield Capital Management Co. LP” was posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this piece of content on another site, it was stolen and reposted in violation of United States and international copyright & trademark law. The original version of this piece of content can be accessed at https://www.dispatchtribunal.com/2019/06/15/charles-river-laboratories-intl-inc-nysecrl-shares-sold-by-westfield-capital-management-co-lp.html.

About Charles River Laboratories Intl.

Charles River Laboratories International, Inc, an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services worldwide. It operates in three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing).

See Also: What is the significance of a dead cat bounce?

Want to see what other hedge funds are holding CRL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Charles River Laboratories Intl. Inc (NYSE:CRL).

Institutional Ownership by Quarter for Charles River Laboratories Intl. (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories Intl. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories Intl. and related companies with MarketBeat.com's FREE daily email newsletter.